0001140361-16-072935.txt : 20160720 0001140361-16-072935.hdr.sgml : 20160720 20160720195124 ACCESSION NUMBER: 0001140361-16-072935 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160718 FILED AS OF DATE: 20160720 DATE AS OF CHANGE: 20160720 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES CENTRAL INDEX KEY: 0001221590 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 161776313 MAIL ADDRESS: STREET 1: 925 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 4 1 doc1.xml FORM 4 X0306 4 2016-07-18 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2016-07-18 2016-07-18 4 M 0 41666 17.54 A 420250 D Common Stock 2016-07-18 2016-07-18 4 S 0 41666 92.72 D 378584 D Common Stock 25758 I Shares held by Bienaime Family Trust Stock Option (right to buy Common Stock) 17.54 2016-07-18 2016-07-18 4 M 0 41666 0 D 2007-05-20 2016-11-19 Common Stock 41666 166668 D Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the sale of these shares pursuant to a marital separation agreement between Mr. Bienaime and his former spouse. The price in column 4 is the weighted average price. The price actually received ranged from $89.75 to $94.32. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects the number of stock options outstanding after the transaction from this specific stock option grant. /s/ Laura Randall Woodhead, Attorney-in-Fact 2016-07-20